RECENT NEWS

The past year has proved challenging for readers, contributors and commercial colleagues alike; however, the team responsible for publication of Pathology in Practice looks forward with some confidence to a better 2021.

Debra Padgett has been confirmed as the IBMS President-Elect, a position that took effect from 1 January 2021. She will work with the current President, Allan Wilson, and will succeed him as President on 1 January 2022.

Joshua Walker, Export Manager at Priorclave, has won the Gambica 2020 Young Talent of the Year Award.

ProPath has announced the addition of SS18-SSX to its antibody library. It is a fusion-specific antibody that is highly sensitive (95%) and specific (100%) for the detection of synovial sarcoma.

In the third article in his series on method comparisons, now published in the December issue, Stephen MacDonald focuses on what differences are expected and acceptable, and what other factors need further investigation.

The team responsible for publication of Pathology in Practice wishes to acknowledge the support received in difficult times over the past months from readers, contributors and commercial colleagues.

In a new report from the Microbiology Society, experts from around the UK explain the desperate need for long-term and ambitious funding for surveillance and research into antimicrobial resistance (AMR).

The Biomedical Science Industry Handbook 2021 is now available as a hard copy and in digital format. It provides comprehensive information on the full range of products and services from the in vitro diagnostics (IVD) industry.

Hummingbird Bioscience, a clinical-stage biotechnology company focused on developing revolutionary therapies for hard-to-drug targets, has announced a collaboration with Tempus, a leader in artificial intelligence (AI) and precision medicine.

Integra Biosciences’ VIAFLO electronic pipettes are making qPCR plate preparation the straightforward process it should be for researchers in the Saint-Geniez laboratory at Harvard Medical School.

As part of Olympus' commitment to providing digital solutions that improve the efficiency of cancer and stem cell research, the Olympus Provi CM20 incubation monitoring system has changed the way cell culture monitoring is conducted.

Boston Cell Standards will present the results of a Canadian study that tested the first system of reference materials for standardisation of oestrogen receptor (ER) testing for breast cancer at the virtual San Antonio Breast Cancer Symposium.

Urgent action is required to reduce the devastating impact of surgical site infections (SSIs) in the UK, according to the report entitled ‘Time to Act: A State of the Nation Report on Surgical Site Infections in the UK’.

CliniSys Group has formed a partnership with Software Testing Solutions (STS) that will support CliniSys’ delivery of automated software testing services for its WinPath Enterprise LIMS and ICE solutions.

In the third article in his series on method comparisons, Stephen MacDonald focuses on what differences are expected and acceptable, and what other factors need further investigation. Read the full feature in the December issue.

Triaging patients presenting with acute respiratory infection symptoms in the influenza season can be a minefield, without the added pressure of a global pandemic. Distinguishing between viral and bacterial infections can inform treatment decisions.

Ibex Medical Analytics has announced a research partnership and joint study with Institut Curie, France’s leading cancer centre, for the first-ever blinded and independent evaluation of an AI solution for breast cancer detection.

Agilent Technologies has launched the Biomarker Pathologist Training Programme, a global initiative created to empower pathologists to score biomarkers accurately and confidently.

A potential breakthrough in the early detection of the neck, head and anal cancers linked to human papillomavirus (HPV) has emerged, based on a highly specific point-of-care blood test that appears to indicate cancer, and predict its course.

The Galleri blood test, developed by GRAIL, can detect early-stage cancers through a simple blood test, and will be piloted with 165,000 patients in a world-first deal struck by NHS England.